Edesa Biotech (EDSA) Non-Current Deferred Tax Liability (2020 - 2023)

Edesa Biotech has reported Non-Current Deferred Tax Liability for 4 years, with the latest figure at $53000.0 in Q3 2023.

• Quarterly Non-Current Deferred Tax Liability rose 231.25% year-over-year to $53000.0 in Q3 2023, while the trailing twelve-month figure through Sep 2023 was $53000.0 (up 231.25% YoY) and the FY2023 annual result came in at $53000.0, up 231.25% from the prior year.
• Non-Current Deferred Tax Liability improved to $53000.0 in Q3 2023 per EDSA's latest filing, from $16000.0 in the prior quarter.
• Over five years, Non-Current Deferred Tax Liability peaked at $53000.0 in Q3 2023 and troughed at $16000.0 in Q3 2022.
• A 4-year average of $32500.0 and a median of $30500.0 in 2020 frame the typical range for Non-Current Deferred Tax Liability.
• The sharpest annual moves came in 2022 and 2023: Non-Current Deferred Tax Liability slumped 63.64% in 2022, then jumped 231.25% in 2023.
• Over 4 years, Non-Current Deferred Tax Liability stood at $17000.0 in 2020, then jumped by 158.82% to $44000.0 in 2021, then plunged by 63.64% to $16000.0 in 2022, then surged by 231.25% to $53000.0 in 2023.
• According to Business Quant data, Non-Current Deferred Tax Liability over the past three periods registered $53000.0, $16000.0, and $44000.0 for Q3 2023, Q3 2022, and Q3 2021 respectively.